Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Karel Hählen"'
Publikováno v:
Haematologica, Vol 93, Iss 9 (2008)
Externí odkaz:
https://doaj.org/article/d7cf74b93a81426291ae13e7db04c896
Autor:
Brenda Gibson, Jacqueline Cloos, Ursula Creutzig, Desiree de Lange, Gertjan J.L. Kaspers, Dirk Reinhardt, Karel Hählen, Christian M. Zwaan, A H Loonen, Bianca F. Goemans
Publikováno v:
Leukemia Research, 34(10), 1302-1307. Elsevier Limited
Leukemia Research, 34, 1302-1307. Elsevier Ltd.
Goemans, B F, Zwaan, C M, Cloos, J, de Lange, D, Loonen, A H, Reinhardt, D, Hahlen, K, Gibson, B E S, Creutzig, U & Kaspers, G J L 2010, ' FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657 ', Leukemia Research, vol. 34, no. 10, pp. 1302-1307 . https://doi.org/10.1016/j.leukres.2010.04.004
Leukemia Research, 34, 1302-1307. Elsevier Ltd.
Goemans, B F, Zwaan, C M, Cloos, J, de Lange, D, Loonen, A H, Reinhardt, D, Hahlen, K, Gibson, B E S, Creutzig, U & Kaspers, G J L 2010, ' FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657 ', Leukemia Research, vol. 34, no. 10, pp. 1302-1307 . https://doi.org/10.1016/j.leukres.2010.04.004
New treatment strategies to improve the outcome of pediatric acute myeloid leukemia (AML) are required as 40% of children diagnosed with AML do not survive. Around 30% of pediatric AML patients harbour a mutation in the tyrosine kinases FLT3 (+/-20%)
Autor:
Geert H.M. van der Linden, Gert R. Dohle, Marry M. van den Heuvel-Eibrink, Friederike G.A.J. Hakvoort-Cammel, Karel Hählen, Niels J. van Casteren
Publikováno v:
Pediatric Blood & Cancer, 52, 108-112. Wiley-Liss Inc.
Background Although it is accepted that pediatric cancer treatment harbors a risk of gonadal damage, large cohort studies using up-to-date fertility markers are lacking. Procedure The aim of our study was to evaluate the gonadal toxicity of childhood
Autor:
Willem Kamps, Alida C. Weidenaar, Jessica C.A. Bouma-ter Steege, Eveline S. J. M. de Bont, Jenny Douwes, Vaclav Fidler, Karel Hählen, Tiny G. J. Meeuwsen-de Boer, Hendrik J. M. de Jonge, Arja ter Elst
Publikováno v:
Anti-Cancer Drugs. 19:45-54
Acute myeloid leukemia (AML) is a disease with a poor prognosis. It has been demonstrated that AML cells express the vascular endothelial growth factors, VEGFA and VEGFC, as well as kinase insert domain-containing receptor (VEGFR2), the main receptor
Autor:
Barbara A. E. de Koning, Maarten Hoijer, Hans A. Büller, Karel Hählen, Rob Pieters, Bertine Philipsen-Geerling
Publikováno v:
Pediatric Blood & Cancer, 48, 532-539. Wiley-Liss Inc.
Pediatric Blood & Cancer, 48(5), 532-539. Wiley-Liss Inc.
Pediatric Blood & Cancer, 48(5), 532-539. Wiley-Liss Inc.
Background Mucositis is one of the most frequent and severe side-effect of chemotherapy in childhood-cancer patients for which there is no prophylaxis available. The efficacy and feasibility of a TGF-β2-enriched feeding for preventing oral and gastr
Autor:
Gertjan J.L. Kaspers, Bianca F. Goemans, Nancy Boeckx, Corine J. Hess, S Corthals, Dirk Reinhardt, Karel Hählen, J.W. van Oostveen, Jacqueline Cloos, Gerrit-Jan Schuurhuis, D de Lange, Quinten Waisfisz, U. Creutzig, Ch. M. Zwaan
Publikováno v:
Cloos, J, Goemans, B F, Hess, C J, van Oostveen, J W, Waisfisz, Q, Corthals, S, de lange, D, Boeckx, N, Hahlen, K, Reinhardt, D, Creutzig, U, Schuurhuis, G J, Zwaan, C M & Kaspers, G J L 2006, ' Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples ', Leukemia, vol. 20, no. 7, pp. 1217-1220 . https://doi.org/10.1038/sj.leu.2404246
Leukemia, 20(7), 1217-1220. Nature Publishing Group
Leukemia, 20, 1217-1220. Nature Publishing Group
Leukemia, 20(7), 1217-1220. Nature Publishing Group
Leukemia, 20, 1217-1220. Nature Publishing Group
In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in paired initial and relapse samples from
Autor:
A H Loonen, Christian M. Zwaan, Bianca F. Goemans, Dirk Reinhardt, Karel Hählen, Gertjan J.L. Kaspers, Amy Harlow, Brenda Gibson, Ursula Creutzig, Michael Heinrich
Publikováno v:
Blood, 106(10), 3532-3537. American Society of Hematology
Goemans, B F, Zwaan, C M, Harlow, A, Loonen, A H, Gibson, B E S, Hählen, K, Reinhardt, D, Creutzig, U, Heinrich, M C & Kaspers, G J L 2005, ' In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets ', Blood, vol. 106, no. 10, pp. 3532-3537 . https://doi.org/10.1182/blood-2005-04-1640
Goemans, B F, Zwaan, C M, Harlow, A, Loonen, A H, Gibson, B E S, Hählen, K, Reinhardt, D, Creutzig, U, Heinrich, M C & Kaspers, G J L 2005, ' In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets ', Blood, vol. 106, no. 10, pp. 3532-3537 . https://doi.org/10.1182/blood-2005-04-1640
Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
Autor:
Michael Heinrich, Ch. M. Zwaan, A H Loonen, Amy Harlow, Soheil Meshinchi, Gertjan J.L. Kaspers, Dirk Reinhardt, Karel Hählen, U Creutzig, M. Miller, Bianca F. Goemans, Martin Zimmermann
Publikováno v:
Leukemia, 19(9), 1536-1542. Nature Publishing Group
Goemans, B F, Zwaan, C M, Miller, M, Zimmermann, M, Harlow, A, Meshinchi, S, Loonen, A H, Hahlen, K, Reinhardt, D, Creutzig, U, Kaspers, G J L & Heinrich, M C 2005, ' Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia ', Leukemia, vol. 19, no. 9, pp. 1536-1542 . https://doi.org/10.1038/sj.leu.2403870
Goemans, B F, Zwaan, C M, Miller, M, Zimmermann, M, Harlow, A, Meshinchi, S, Loonen, A H, Hahlen, K, Reinhardt, D, Creutzig, U, Kaspers, G J L & Heinrich, M C 2005, ' Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia ', Leukemia, vol. 19, no. 9, pp. 1536-1542 . https://doi.org/10.1038/sj.leu.2403870
Activating mutations in RAS and receptor tyrosine kinases such as KIT and FLT3 are hypothesized to cooperate with chimeric transcription factors in the pathogenesis of acute myeloid leukemia (AML). To test this hypothesis, we genotyped 150 pediatric
Autor:
Jos P.M. Bökkerink, Gertjan J.L. Kaspers, G. Kardos, E. S. J. M. de Bont, A. van der Does-van den Berg, S S N de-Graaf, Albert Postma, R.S. Weening, E. R. Van Wering, Christian M. Zwaan, C Korbijn, Karel Hählen
Publikováno v:
Leukemia, 19, 2063-71
Leukemia, 19, 12, pp. 2063-71
Leukemia, 19(12), 2063-2071. Nature Publishing Group
Kardos, G, Zwaan, C M, Kaspers, G J L, de Graaf, SS, de Bont, ES, Postma, A, Bokkerink, JP, Weening, R S, van den Berg, A, van Wering, E R, Korbijn, C & Hahlen, K 2005, ' Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials ', Leukemia, vol. 19, no. 12, pp. 2063-2071 . https://doi.org/10.1038/sj.leu.2403873
Leukemia, 19, 12, pp. 2063-71
Leukemia, 19(12), 2063-2071. Nature Publishing Group
Kardos, G, Zwaan, C M, Kaspers, G J L, de Graaf, SS, de Bont, ES, Postma, A, Bokkerink, JP, Weening, R S, van den Berg, A, van Wering, E R, Korbijn, C & Hahlen, K 2005, ' Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials ', Leukemia, vol. 19, no. 12, pp. 2063-2071 . https://doi.org/10.1038/sj.leu.2403873
Contains fulltext : 49234.pdf (Publisher’s version ) (Closed access) This report describes the long-term follow-up data of three consecutive Dutch Childhood Oncology Group acute myeloid leukemia (AML) protocols. A total of 303 children were diagnos
Autor:
Saskia Buitendijk, Karel Hählen, F. G. A. J. Hakvoort-Cammel, Marry M. van den Heuvel-Eibrink
Publikováno v:
Pediatric Blood & Cancer. 43:8-16
Background. To reduce radiotherapy (XRT) induced toxicity of treatment of children with Hodgkin disease (HD) while maintaining a high cure rate, we introduced a risk-adapted protocol consisting of chemotherapy (CT) alone in 1984. Procedure. The outco